Indian billionaires to buy Lotus Surgicals for INR 3.8 billion
Indian billionaire Azim Premji's private equity and venture capitalist arm, Premji Invest, and Tube Investments, together will acquire Lotus Surgicals for INR 3.8.
Drugs
Medical
Pharma
Drugs
Medical
Pharma
India inks pact with Huwel Lifesciences to make rapid real-time PCR reagents
ndia’s Technology Development Board has signed a pact with Huwel Lifesciences for the validation and commercialisation of rapid real-time PCR reagents for storage.
Drugs
Health
Pharma
India caps trade margins on 42 anti-cancer medicines
India has put a cap on the trade margin of 42 selected non-scheduled anti-cancer medicines, including ribociclib, which is used to treat breast.
Drugs
Medical
Pharma
Yemen, Lebanon allege India’s Celon Labs’ drug ‘substandard’
The WHO has issued a medical product alert on a contaminated cancer and autoimmune disease treatment drug made by Hyderabad, India-based Celon Laboratories,.
Drugs
Medical
Pharma
Ransomware group behind cyberattack: Sun Pharma
A ransomware group has breached the information security network of India's Sun Pharmaceuticals unit, and there is a possibility that "file systems, business and personal.
Health
Pharma
World Bank loans India $1 billion to aid healthcare sector
The Indian government and the World Bank signed two agreements to support and enhance the development of the health sector in the south.
Medical
Pharma
Wipro unveils ‘tamper-proof’ self-verifiable digital wallet
India's WiproLab45 unveiled its Decentralized Identity and Credential Exchange (DICE) ID to put the user in control of their medical data, approval to.
Drugs
Pharma
Global Pharma recalls eye drops after FDA contamination warning
India-based Global Pharma Healthcare voluntarily recalled all lots of its artificial tears lubricant eye drops after the USFDA reported possible contamination.
Drugs
Medical
Pharma
Max Healthcare profit jumps 7%, to raise INR 42 billion in debt
Max Healthcare, one of India’s largest private hospital chains, reported a 7% rise in profit after tax, on revenue of INR 15.6 billion,.
Drugs
Health
Pharma
Stelis Biopharma to be pure play CDMO firm, may list ‘near term’
Stelis Biopharma, a division of India’s Strides Pharma Science, will become a full-fledged contract development and manufacturing firm and may list “near-term.